The effects of rheumatoid arthritis on labor force participation, work performance, and healthcare costs in two workplace samples

Journal of Occupational and Environmental Medicine

Volumn 50, Issue 1, 2008, Pages 88-98

  Kessler, Ronald C ^a   Maclean, J Ross ^b   Petukhova, Maria ^a   Sarawate, Chaitanya A ^a   Short, Louise ^a   Li, Tracy T ^b   Stang, Paul E ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; NONSTEROID ANTIINFLAMMATORY AGENT;

ABSENTEEISM; ADULT; ARTHRITIS; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DRUG COST; EMPLOYEE; FEMALE; HEALTH AND WORK PERFORMANCE QUESTIONNAIRE; HEALTH CARE COST; HEALTH STATUS; HUMAN; INDUSTRIAL WORKER; JOB PERFORMANCE; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; QUESTIONNAIRE; REGRESSION ANALYSIS; RHEUMATOID ARTHRITIS; SELF REPORT; WORKPLACE;

EID: 38049187631     PISSN: 10762752     EISSN: None     Source Type: Journal    
DOI: 10.1097/JOM.0b013e31815bc1aa     Document Type: Article

References (49)

1. Alamanos Y, Voulgari PV, Drosos AA. Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review. Semin Arthritis Rheum. 2006;36:182-188.
2. Silman AJ, Pearson JE. Epidemiology and genetics of rheumatoid arthritis. Arthritis Res. 2002;4(suppl 3):S265-S272.
3. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet. 2001;358:903-911.
4. Pugner KM, Scott DI, Holmes JW, Hieke K. The costs of rheumatoid arthritis: an international long-term view. Semin Arthritis Rheum. 2000;29:305-320.
5. Deighton CM, George E, Kiely PDW, Ledingham J, Luqmani RA, Scott DGI. Updating the British Society for Rheumatology guidelines for anti-tumour necrosis factor therapy in adult rheumatoid arthritis (again). Rheumatology. 2006;45:649-652.
6. Bansback NJ, Regier DA, Ara R, et al. An overview of economic evaluations for drugs used in rheumatoid arthritis: focus on tumour necrosis factor-alpha antagonists. Drugs. 2005;65:473-496.
7. Doan QV, Chiou CF, Dubois RW. Review of eight pharmacoeconomic studies of the value of biologic DMARDs (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritis. J Manag Care Pharm. 2006;12:555-569.
8. Lyseng-Williamson KA, Plosker GL. Etanercept: a pharmacoeconomic review of its use in rheumatoid arthritis. Pharmacoeconomics. 2004;22:1071-1095.
9. Nurmohamed MT, Dijkmans BA. Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis. Drugs. 2005;65:661-694.
10. Chen YF, Jobanputra P, Barton P, et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess. 2006;10:iii-iv, xi-xiii, 1-229.
11. Bansback NJ, Brennan A, Ghatnekar O. Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden. Ann Rheum Dis. 2005;64:995-1002.
12. Welsing PM, Severens JL, Hartman M, van Riel PL, Laan RF. Modeling the 5-year cost effectiveness of treatment strategies including tumor necrosis factor-blocking agents and leflunomide for treating rheumatoid arthritis in the Netherlands. Arthritis Rheum. 2004;51:964-973.
13. Wong JB, Singh G, Kavanaugh A. Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis. Am J Med. 2002;113:400-408.
14. Kobelt G, Lindgren P, Lindroth Y, Jacobson L, Eberhardt K. Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis. Rheumatology. 2005;44:1169-1175.
15. Vogenberg FR, Holland JP, Liebeskind D. Employer benefit design considerations for the era of biotech drugs. J Occup Environ Med. 2007;49:626-632.
16. Kessler RC, Richling DE, Sullivan S. Rationalizing employer health care spending by measuring workplace value. Health Product Manag. 2004;3:4-8.
17. Kvien TK, Glennas A, Knudsrod OG, Smedstad LM. The validity of self-reported diagnosis of rheumatoid arthritis: results from a population survey followed by clinical examinations. J Rheumatol. 1996;23:1866-1871.
18. Guillemin F, Saraux A, Fardellone P, Guggenbuhl P, Behier JM, Coste J. Detection of cases of inflammatory rheumatic disorders: performance of a telephone questionnaire designed for use by patient interviewers. Ann Rheum Dis. 2003;62:957-963.
19. Saraux A, Guillemin F, Fardellone P, et al. Agreement between rheumatologist visit and lay interviewer telephone survey for screening for rheumatoid arthritis and spondyloarthropathy. Joint Bone Spine. 2004;71:44-50.
20. Katz JN, Barrett J, Liang MH, et al. Sensitivity and positive predictive value of Medicare Part B physician claims for rheumatologic diagnoses and procedures. Arthritis Rheum. 1997;40:1594-1600.
21. Singh JA, Holmgren AR, Noorbaloochi S. Accuracy of Veterans Administration databases for a diagnosis of rheumatoid arthritis. Arthritis Rheum. 2004;51:952-957.
22. Kessler RC, Ames M, Hymel PA, et al. Using the WHO Health and Work Performance Questionnaire (HPQ) to evaluate the indirect workplace costs of illness. J Occup Environ Med. 2004;46:S23-S27.
23. Kessler RC, Barber C, Beck A, et al. The World Health Organization Health and Work Performance Questionnaire (HPQ). J Occup Environ Med. 2003;45:156-174.
24. Kessler RC, Greenberg PE, Mickelson KD, Meneades LM, Wang PS. The effects of chronic medical conditions on work loss and work cutback. J Occup Environ Med. 2001;43:218-225.
25. Wang PS, Beck A, Berglund P, et al. Chronic medical conditions and work performance in the health and work performance questionnaire calibration surveys. J Occup Environ Med. 2003;45:1303-1311.
26. National Center for Health Statistics. Health, United States, 2004. Hyattsville, Maryland: U.S. Government Printing Office; 2004.
27. Schoenborn CA, Adams PF, Schiller JS. Summary health statistics for the U.S. population: National Health Interview Survey, 2000. Vital Health Stat 10. 2003: 1-83.
28. Knight M, Stewart-Brown S, Fletcher L. Estimating health needs: the impact of a checklist of conditions and quality of life measurement on health information derived from community surveys. J Public Health Med. 2001;23:179-186.
29. Baker M, Stabile M, Deri C. What do self-reported, objective measures of health measure? NBER Working Paper. 2001;8419.
30. Edwards WS, Winn DM, Kurlantzick V, et al. Evaluation of National Health Interview Survey Diagnostic Reporting. National Center for Health Statistics. Vital Health Stat. 1994;2:120.
31. Revicki DA, Rentz AM, Dubois D, et al. Gastroparesis Cardinal Symptom Index (GCSI): development and validation of a patient reported assessment of severity of gastroparesis symptoms. Qual Life Res. 2004;13:833-844.
32. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980;23:137-145.
33. Memel DS, Kirwan JR, Langley C, Hewlett S, Hehir M. Prediction of successful application for disability benefits for people with arthritis using the Health Assessment Questionnaire. Rheumatology (Oxford). 2002;41:100-102.
34. Wong JB, Ramey DR, Singh G. Long-term morbidity, mortality, and economics of rheumatoid arthritis. Arthritis Rheum. 2001;44:2746-2749.
35. Boers M. Does sex of rheumatoid arthritis patients matter? Lancet. 1998;352:419-420.
36. Barrett EM, Scott DG, Wiles NJ, Symmons DP. The impact of rheumatoid arthritis on employment status in the early years of disease: a UK community-based study. Rheumatology (Oxford). 2000;39:1403-1409.
37. Sokka T, Kautiainen H, Mottonen T, Hannonen P. Work disability in rheumatoid arthritis 10 years after the diagnosis. J Rheumatol. 1999;26:1681-1685.
38. Young A, Dixey J, Kulinskaya E, et al. Which patients stop working because of rheumatoid arthritis? Results of five years' follow up in 732 patients from the Early RA Study (ERAS). Ann Rheum Dis. 2002;61:335-340.
39. de Croon EM, Sluiter JK, Nijssen TF, Dijkmans BA, Lankhorst GJ, Frings-Dresen MH. Predictive factors of work disability in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis. 2004;63:1362-1367.
40. Choi HK, Seeger JD, Kuntz KM. A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis. Arthritis Rheum. 2000;43:2316-2327.
41. Choi HK, Seeger JD, Kuntz KM. A cost effectiveness analysis of treatment options for methotrexate-naive rheumatoid arthritis. J Rheumatol. 2002;29:1156-1165.
42. Weng X, Liu L, Barcellos LF, Allison JE, Herrinton LJ. Clustering of inflammatory bowel disease with immune mediated diseases among members of a Northern California-managed care organization. Am J Gastroenterol. 2007;102:1429-1435.
43. Loehrl TA, Smith TL. Inflammatory and granulomatous lesions of the larynx and pharynx. Am J Med. 2001;111(suppl 8A):113S-117S.
44. Garcia EB, Michaud K, Wolfe F. Gastrointestinal prophylactic therapy among patients with arthritis treated by rheumatology specialists. J Rheumatol. 2006;33:779-784.
45. Zautra AJ, Fasman R, Parish BP, Davis MC. Daily fatigue in women with osteoarthritis, rheumatoid arthritis, and fibromyalgia. Pain. 2007;128:128-135.
46. Shibuya K, Hagino H, Morio Y, Teshima R. Cross-sectional and longitudinal study of osteoporosis in patients with rheumatoid arthritis. Clin Rheumatol. 2002;21:150-158.
47. Heckman JJ, Ichimura H, Smith JC, Todd P. Characterizing selection bias. Econometrica. 1997;66:1017-1098.
48. Heckman JJ. Shadow prices, market wages, and labor supply. Econometrica. 1974;42:679-694.
49. Klareskog L, Padyukov L, Alfredsson L. Smoking as a trigger for inflammatory rheumatic diseases. Curr Opin Rheumatol. 2007;19:49-54.